The Southwest Oncology Group Cancer Research Program of the University of Texas Health Science Center at San Antonio is a member institution multidisciplinary program dedicated to accrual of high numbers of patients to the studies of the Southwest Oncology Group and to high quality data collection from the member institution and its Cooperative Group Outreach Program (CGOP) Affiliates. The Principal Investigator and 48 collaborating investigators from Medical Oncology, Hematology, Surgical Oncology, Radiation Oncology, and Pathology maintain 20 uninterrupted years of participation in this cooperative clinical trials program. This program has achieved first or second rank among all participating member institutions in patient accrual for the past two years. 1,202 patients have been enrolled to Group studies by the member institution and its CGOPs from l/l/92 to 12/31/96 (363 patients by the member institution alone). Of these patients, 642 or 53 percent were women (217 or 60 percent of the member institution accrual), 185 or 15 percent were Hispanic (126 or 35 percent of the member institution accrual), and 152 or 13 percent were African-American (35 or 10 percent of the member institution accrual). The program has recruited 7 new CGOP affiliates for a total of 17 CGOP institutions for which UTHSCSA serves as research base. This application seeks support of a member institution clinical trials organization capable of major patient accrual from a broad sample of patient candidates to the clinical trials of the Southwest Oncology Group, submission of high quality data, and continued involvement of its investigators in major scientific and administrative activities in the Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA022433-25
Application #
6489020
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-01-01
Project End
2003-12-31
Budget Start
2002-02-27
Budget End
2002-12-31
Support Year
25
Fiscal Year
2002
Total Cost
$263,942
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8

Showing the most recent 10 out of 257 publications